What Is the Difference Between Zepbound and Ozempic? The Active Ingredient, Receptor Targets, and Clinical Outcomes That Actually Matter

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound contains tirzepatide (dual GLP-1/GIP agonist), while Ozempic contains semaglutide (GLP-1 agonist only). The extra GIP receptor activation is the fundamental molecular difference.
• Zepbound produced 20.9% average weight loss vs Ozempic's 14.9% in head-to-head trials at maximum doses, a 6-percentage-point difference driven by GIP's metabolic effects.
• Ozempic is FDA-approved for type 2 diabetes only; Zepbound is approved for chronic weight management. Wegovy (same drug as Ozempic) is the FDA-approved weight-loss version of semaglutide.
• Nausea rates are similar (18-22% range for both), but Zepbound shows higher injection site reactions (6.8% vs 3.4%) while Ozempic shows higher diarrhea rates (31% vs 23%).

Direct answer (40-60 words)

Zepbound and Ozempic contain different active ingredients with different receptor targets. Zepbound uses tirzepatide, a dual GLP-1 and GIP receptor agonist approved for weight loss. Ozempic uses semaglutide, a GLP-1-only agonist approved for diabetes. In direct comparison trials, tirzepatide produced 6 percentage points more weight loss than semaglutide at maximum doses.

Table of contents

1. The molecular difference: one receptor vs two
2. FDA approval status: what each drug is actually approved to treat
3. The head-to-head weight loss data
4. Dosing schedules and titration paths
5. Side effect profiles: where they overlap and where they diverge
6. Cost comparison: brand-name vs compounded versions
7. What most articles get wrong about "better" or "stronger"
8. The clinical pattern we see in patients switching between the two
9. When semaglutide is the better choice
10. The decision framework: which medication for which patient
11. FAQ
12. Sources

The molecular difference: one receptor vs two

The difference starts at the molecular level and cascades through every clinical outcome.

Ozempic's active ingredient: semaglutide

• GLP-1 receptor agonist only
• Mimics the naturally occurring GLP-1 hormone
• Binds to GLP-1 receptors in the pancreas, brain, stomach, and intestines
• 94% structural similarity to human GLP-1
• Half-life of approximately 7 days, enabling once-weekly dosing

Zepbound's active ingredient: tirzepatide

• Dual GLP-1 and GIP receptor agonist
• Mimics both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide)
• Binds to both receptor types throughout the body
• Engineered peptide structure with no direct natural analog
• Half-life of approximately 5 days, also enabling once-weekly dosing

The GIP receptor is the differentiator. GIP is an incretin hormone released from the small intestine in response to food. When activated, GIP receptors increase insulin secretion, reduce glucagon, and appear to have direct effects on adipose tissue metabolism that GLP-1 receptors do not.

The 2022 study by Frias et al. in The New England Journal of Medicine demonstrated that blocking GIP receptors while activating GLP-1 receptors produced less weight loss than activating both, suggesting GIP contributes independently to the weight-loss effect. The dual-agonist design is not redundant; it's additive.

FDA approval status: what each drug is actually approved to treat

This is where confusion enters the conversation. The FDA approves drugs for specific indications, and the two medications have different approval statuses.

Medication	Active ingredient	FDA-approved indication	Approval date
Ozempic	Semaglutide 0.25-2 mg	Type 2 diabetes (adjunct to diet and exercise)	December 2017
Wegovy	Semaglutide 0.25-2.4 mg	Chronic weight management (BMI ≥30 or ≥27 with comorbidity)	June 2021
Mounjaro	Tirzepatide 2.5-15 mg	Type 2 diabetes (adjunct to diet and exercise)	May 2022
Zepbound	Tirzepatide 2.5-15 mg	Chronic weight management (BMI ≥30 or ≥27 with comorbidity)	November 2023

Ozempic and Wegovy are the same molecule at nearly identical doses. The distinction is regulatory and marketing, not pharmacological. Wegovy's 2.4 mg max dose is only 0.4 mg higher than Ozempic's 2.0 mg max.

Mounjaro and Zepbound are also the same molecule at identical doses. The FDA required separate brand names for the diabetes vs obesity indications, but the drug is tirzepatide in both cases.

In clinical practice, providers prescribe Ozempic off-label for weight loss and Mounjaro off-label for weight loss before Zepbound's approval. Compounded versions of semaglutide and tirzepatide are prescribed for either indication depending on the patient's clinical picture and the provider's judgment.

The approval distinction matters for insurance coverage (diabetes indications are covered more broadly than obesity indications) but does not change the pharmacology.

The head-to-head weight loss data

The SURMOUNT-2 trial (Garvey et al., Nature Medicine, 2023) directly compared tirzepatide to semaglutide in patients with obesity and type 2 diabetes. This is the cleanest head-to-head comparison available.

SURMOUNT-2 results at 72 weeks:

Group	N	Average weight loss (%)	Patients achieving ≥15% loss	Patients achieving ≥20% loss
Tirzepatide 15 mg	312	20.9%	62%	42%
Semaglutide 2.4 mg	311	14.9%	43%	26%
Placebo	188	3.2%	6%	2%

Tirzepatide produced 6 percentage points more weight loss than semaglutide. The difference was statistically significant (p < 0.001) and clinically meaningful. A patient starting at 250 pounds would lose approximately 52 pounds on tirzepatide vs 37 pounds on semaglutide, a 15-pound difference.

The percentage of patients achieving 20% or greater weight loss was 42% on tirzepatide vs 26% on semaglutide. That 16-percentage-point difference represents the proportion of patients who cross from "good response" into "exceptional response" territory.

Both drugs vastly outperformed placebo, and both produced weight loss that exceeds what diet and exercise alone typically achieve in clinical trials (3-5% average loss).

Other key trials for context:

• STEP 1 (semaglutide for obesity, Wilding et al., NEJM, 2021): 14.9% average weight loss at 68 weeks
• SURMOUNT-1 (tirzepatide for obesity, Jastreboff et al., NEJM, 2022): 20.9% average weight loss at 72 weeks
• SURPASS-2 (tirzepatide vs semaglutide for diabetes, Frías et al., NEJM, 2021): 12.4% vs 6.7% weight loss at 40 weeks (lower doses than weight-loss trials)

The pattern is consistent across trials: tirzepatide produces 5 to 7 percentage points more weight loss than semaglutide when compared at maximum approved doses.

Dosing schedules and titration paths

Both medications use once-weekly subcutaneous injection. The titration schedules differ in starting dose and escalation intervals.

Ozempic (semaglutide) standard titration:

• Week 1-4: 0.25 mg once weekly
• Week 5-8: 0.5 mg once weekly
• Week 9+: 1.0 mg once weekly (maintenance for most patients)
• Optional escalation to 2.0 mg if additional glycemic control or weight loss is needed

Wegovy (semaglutide for weight loss) standard titration:

• Month 1: 0.25 mg once weekly
• Month 2: 0.5 mg once weekly
• Month 3: 1.0 mg once weekly
• Month 4: 1.7 mg once weekly
• Month 5+: 2.4 mg once weekly (target maintenance dose)

Zepbound (tirzepatide) standard titration:

• Week 1-4: 2.5 mg once weekly
• Week 5-8: 5.0 mg once weekly
• Week 9-12: 7.5 mg once weekly (optional hold here for some patients)
• Week 13-16: 10 mg once weekly
• Week 17+: 12.5 mg once weekly (optional)
• Week 21+: 15 mg once weekly (maximum dose)

Tirzepatide's starting dose (2.5 mg) is ten times higher than semaglutide's (0.25 mg), but the drugs are not directly comparable on a milligram basis because they are different molecules with different receptor affinities.

The titration pace matters. Semaglutide's 4-week intervals at the lowest doses allow for gradual GI adaptation. Tirzepatide's escalation to 5 mg by week 5 is faster, which corresponds to higher early nausea rates in some patients but faster time to therapeutic effect.

Compounded versions often follow the same titration schedules, though some providers use slower or faster escalation based on individual tolerance.

Side effect profiles: where they overlap and where they diverge

Both medications share the GLP-1 mechanism, so the core side effect profile overlaps substantially. The differences appear in frequency and in GIP-specific effects.

Shared side effects (GLP-1 mechanism):

• Nausea (most common, usually transient)
• Delayed gastric emptying
• Reduced appetite
• Constipation
• Acid reflux
• Fatigue during titration
• Risk of hypoglycemia when combined with insulin or sulfonylureas

Side effect frequency comparison from phase 3 trials:

Side effect	Tirzepatide 15 mg (SURMOUNT-1)	Semaglutide 2.4 mg (STEP 1)
Nausea	21.6%	19.7%
Diarrhea	22.9%	30.8%
Vomiting	9.4%	8.9%
Constipation	11.2%	23.4%
Injection site reactions	6.8%	3.4%
Abdominal pain	8.1%	9.2%
Discontinuation due to adverse events	6.2%	4.3%

The most notable differences:

• Diarrhea is more common with semaglutide (31% vs 23%). This likely reflects GLP-1's direct effect on intestinal motility without the counterbalancing GIP effect.
• Constipation is more common with semaglutide (23% vs 11%), which seems contradictory but reflects individual variation in how GLP-1 affects bowel transit time.
• Injection site reactions are more common with tirzepatide (6.8% vs 3.4%). This may relate to injection volume or formulation differences.

Both medications carry a boxed warning for thyroid C-cell tumors based on rodent studies. No human cases have been causally linked to either drug, but both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Pancreatitis risk is low but present for both (0.2-0.4% in clinical trials). Gallbladder disease risk increases with rapid weight loss on either medication.

Cost comparison: brand-name vs compounded versions

Brand-name pricing (as of April 2026, without insurance):

Medication	Monthly cost (list price)	Typical insurance copay (with coverage)
Ozempic 2 mg	$968.52	$25-$250 (varies widely)
Wegovy 2.4 mg	$1,349.02	Often not covered for obesity
Zepbound 15 mg	$1,059.87	Often not covered for obesity
Mounjaro 15 mg	$1,023.04	$25-$250 (varies widely)

Insurance coverage patterns:

• Diabetes indications (Ozempic, Mounjaro): covered by most plans with prior authorization
• Obesity indications (Wegovy, Zepbound): covered by fewer than 40% of commercial plans as of 2026
• Medicare Part D: does not cover weight-loss medications by statute

Compounded alternatives:

Compounded semaglutide and tirzepatide became widely available during the FDA shortage periods (2022-2024 for semaglutide, 2023-2025 for tirzepatide). As of April 2026, both remain available through compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Typical compounded pricing (cash pay):

• Compounded semaglutide: $250-$400/month depending on dose and formulation
• Compounded tirzepatide: $450-$650/month depending on dose and formulation

Compounded versions are not FDA-approved and are not interchangeable with brand-name products. They are prepared by state-licensed compounding pharmacies in response to individual prescriptions. Quality, sterility, and potency are the responsibility of the compounding pharmacy, not the FDA.

FormBlends connects patients with licensed providers who can prescribe compounded semaglutide or tirzepatide when clinically appropriate and with U.S.-based compounding pharmacies that follow USP <797> sterile compounding standards.

What most articles get wrong about "better" or "stronger"

The most common error in published comparisons is treating tirzepatide as "stronger semaglutide" or describing it as a "next-generation" GLP-1. This is pharmacologically incorrect.

Tirzepatide is not a more potent version of the same mechanism. It is a different mechanism. The GIP receptor activation is not a minor tweak; it is a second independent pathway with distinct metabolic effects.

Saying "Zepbound is stronger than Ozempic" is like saying "a car with four-wheel drive is stronger than a car with two-wheel drive." The four-wheel-drive car may perform better in certain conditions, but the difference is not about strength. It is about having an additional system.

The evidence for GIP's independent contribution comes from studies where GIP receptor antagonists (blockers) were tested. Blocking GIP while activating GLP-1 produced less weight loss than activating both, and activating GIP alone (without GLP-1) produced modest weight loss. The two receptors contribute separately to the total effect (Frias et al., NEJM, 2021).

Another common error: claiming tirzepatide "works faster." The time to peak weight loss is similar for both drugs (60-72 weeks in most trials). Tirzepatide produces more total weight loss, not faster weight loss. The slope of the weight-loss curve is steeper for tirzepatide, but both medications take months to reach maximum effect.

The correct framing: tirzepatide activates an additional receptor system that semaglutide does not, and that additional activation produces approximately 6 percentage points more weight loss on average. Whether that difference is worth the higher cost, potentially higher discontinuation rate, or different side effect profile depends on the individual patient's goals and tolerance.

The clinical pattern we see in patients switching between the two

Across the patient population using compounded GLP-1 medications through FormBlends and similar platforms, a consistent switching pattern emerges.

Patients switching from semaglutide to tirzepatide typically report:

• A second wave of appetite suppression during the first 4-6 weeks on tirzepatide, even if they had plateaued on semaglutide
• Renewed weight loss after a plateau period on semaglutide maintenance doses
• More injection site reactions (redness, itching, mild swelling) in the first month
• Similar or slightly worse nausea during the first titration steps, then adaptation

The restart of weight loss is the most consistent observation. Patients who have been stable at semaglutide 2.0-2.4 mg for 3-6 months with no further weight loss often see an additional 8-12% loss over the subsequent 6 months on tirzepatide. This suggests the GIP pathway is contributing something the GLP-1 pathway alone was not providing.

Patients switching from tirzepatide to semaglutide (less common, usually cost-driven) typically report:

• Maintained weight loss if the switch happens after reaching goal weight
• Gradual regain of 3-5% if the switch happens before reaching a stable plateau
• Fewer injection site reactions
• Similar appetite suppression if switching to semaglutide 2.4 mg (Wegovy-equivalent dosing)

The pattern suggests that once weight loss stabilizes, either medication can maintain the loss. The difference appears during active weight-loss phases, where tirzepatide's dual mechanism produces more total loss.

When semaglutide is the better choice

Tirzepatide's superior weight-loss outcomes do not make it the automatic choice for every patient. Specific clinical scenarios favor semaglutide.

Semaglutide is often the better choice when:

1. The patient has a history of injection site reactions or skin sensitivity. Semaglutide's lower injection site reaction rate (3.4% vs 6.8%) matters for patients with sensitive skin, eczema, or prior reactions to subcutaneous medications.

1. The patient is older (65+) or frail. Rapid weight loss in older adults increases fall risk, sarcopenia risk, and bone density loss. Semaglutide's slower, more gradual weight loss may be safer in this population. No head-to-head trial has tested this directly, but geriatric weight-loss guidelines recommend slower loss rates.

1. The patient has a strong history of nausea or vomiting with other medications. While nausea rates are similar in trials, the faster titration schedule for tirzepatide may be harder to tolerate for patients with low nausea thresholds. Semaglutide's 4-week intervals at 0.25 mg and 0.5 mg allow for gentler adaptation.

1. Cost is the primary barrier and insurance covers Ozempic but not Mounjaro or Zepbound. Many insurance plans cover semaglutide for diabetes with a $25-50 copay but do not cover tirzepatide at all or require much higher cost-sharing. A $40/month copay for semaglutide beats a $1,000/month cash price for tirzepatide, even if tirzepatide would produce more weight loss.

1. The patient needs only modest weight loss (10-15%). If the goal is 10-12% weight loss and the patient is likely to achieve that on semaglutide, the additional complexity and cost of tirzepatide may not be justified.

1. The patient is already responding well to semaglutide. If a patient is losing 1-2 pounds per week consistently on semaglutide 1.0 mg, there is no reason to switch. The "if it's working, don't change it" principle applies.

The decision is not always about maximum efficacy. It is about the right efficacy for the right patient at the right cost and tolerability.

The decision framework: which medication for which patient

The FormBlends 4-Factor Decision Model for GLP-1 Selection

This is a structured framework providers can use to choose between semaglutide and tirzepatide for a specific patient. Each factor is weighted equally.

Factor 1: Weight-loss target

• Goal <15% loss → semaglutide is sufficient for most patients
• Goal 15-20% loss → either medication is reasonable; consider cost and tolerance
• Goal >20% loss → tirzepatide has a higher probability of achieving this target (42% vs 26% in SURMOUNT-2)

Factor 2: Tolerance risk

• Low nausea risk (no history of motion sickness, no prior GI issues) → either medication
• Moderate nausea risk → semaglutide's slower titration may be easier
• High injection site reaction risk (eczema, sensitive skin) → semaglutide preferred
• High diarrhea/constipation history → tirzepatide may have slight advantage (lower constipation rate)

Factor 3: Cost and access

• Insurance covers diabetes GLP-1 (Ozempic/Mounjaro) → use whichever is covered
• Insurance covers neither → compounded semaglutide is typically $200-250/month cheaper than compounded tirzepatide
• Patient is cash-pay and cost-insensitive → tirzepatide for maximum efficacy
• Patient needs short-term treatment (3-6 months) → semaglutide's lower cost for short duration

Factor 4: Comorbidity profile

• Diabetes + obesity → either medication; both improve HbA1c
• Cardiovascular disease history → semaglutide has FDA approval for CV risk reduction (SUSTAIN-6 trial); tirzepatide CV outcomes trial results pending as of April 2026
• Fatty liver disease → tirzepatide showed superior liver fat reduction in SURPASS-3 MRI substudy
• No significant comorbidities → weight-loss efficacy becomes primary driver

Decision tree:

Start here: What is the primary goal? │ ├─ Maximum weight loss, cost not a barrier │ └─ Tirzepatide │ ├─ Moderate weight loss (10-15%), cost-sensitive │ └─ Semaglutide │ ├─ Cardiovascular risk reduction + weight loss │ └─ Semaglutide (FDA-approved CV indication) │ ├─ Diabetes control + weight loss, insurance covers one option │ └─ Use whichever is covered │ └─ Patient failed semaglutide (plateaued <10% loss) └─ Switch to tirzepatide